ebomi
Colour theme
Sign in
Insider · CIK 0001253170

Akkaraju Srinivas

CIK 0001253170 Name as filed on the most recent filing

Filed as Akkaraju Srinivas (92)

227 transaction lines · from 92 filings · filed 2004-06-04 to 2026-05-22 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

188 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2022-01-19 P, Open-market purchase Graphite Bio, Inc.GRPH 504,181, acquired Open Form 4 filing 0001209191-22-004346
2021-12-15 P, Open-market purchase Graphite Bio, Inc.GRPH 227,533, acquired Open Form 4 filing 0001209191-21-070500
2021-11-22 P, Open-market purchase Graphite Bio, Inc.GRPH 2,047,103, acquired Open Form 4 filing 0001209191-21-066742
2021-11-15 P, Open-market purchase Chinook Therapeutics, Inc.KDNY 17,010,000, acquired Open Form 4 filing 0001209191-21-064987
2021-10-15 P, Open-market purchase Graphite Bio, Inc.GRPH 28,727, acquired Open Form 4 filing 0001209191-21-060627
2021-10-14 P, Open-market purchase Graphite Bio, Inc.GRPH 38,750, acquired Open Form 4 filing 0001209191-21-060627
2021-10-13 P, Open-market purchase Graphite Bio, Inc.GRPH 600,188, acquired Open Form 4 filing 0001209191-21-060627
2021-10-08 P, Open-market purchase Graphite Bio, Inc.GRPH 984,000, acquired Open Form 4 filing 0001209191-21-060060
2021-10-07 P, Open-market purchase Graphite Bio, Inc.GRPH 134,774, acquired Open Form 4 filing 0001209191-21-060060
2021-10-06 P, Open-market purchase Graphite Bio, Inc.GRPH 850,199, acquired Open Form 4 filing 0001209191-21-060060
2021-08-18 P, Open-market purchase Chinook Therapeutics, Inc.KDNY 2,497,830, acquired Open Form 4 filing 0001209191-21-052814
2021-06-29 P, Open-market purchase Graphite Bio, Inc.GRPH 2 lines 8,500,000, acquired Open Form 4 filing 0001209191-21-044507
2021-03-12 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 3,129,630, acquired Open Form 4 filing 0001104659-21-035758
2021-03-10 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 2 lines 1,886,622, acquired Open Form 4 filing 0001104659-21-035758
2020-08-18 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 2,076,724, disposed Open Form 4 filing 0001104659-20-096870
2020-08-17 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 9,672, disposed Open Form 4 filing 0001104659-20-096870
2020-07-01 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 50,966, disposed Open Form 4 filing 0001104659-20-081190
2020-06-25 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 612,850, disposed Open Form 4 filing 0001104659-20-076997
2020-06-24 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 539,788, disposed Open Form 4 filing 0001104659-20-076997
2020-06-23 S, Open-market sale Syros Pharmaceuticals, Inc.SYRS 565,930, disposed Open Form 4 filing 0001104659-20-076997
2020-05-05 S, Open-market sale Seattle Genetics Inc /WASGEN 1,421,710, disposed Open Form 4 filing 0001203311-20-000025
2019-12-02 P, Open-market purchase Aravive, Inc.ARAV 999,998, acquired Open Form 4 filing 0000899243-19-028342
2019-11-21 S, Open-market sale Seattle Genetics Inc /WASGEN 2 lines 2,096,120, disposed Open Form 4 filing 0001203311-19-000063
2019-08-28 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 314,086, acquired Open Form 4 filing 0001104659-19-048230
2019-08-22 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 75,874, acquired Open Form 4 filing 0001104659-19-047186
2019-08-21 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 1,946,480, acquired Open Form 4 filing 0001104659-19-047186
2019-08-20 P, Open-market purchase Intercept Pharmaceuticals, Inc.ICPT 2,476,223, acquired Open Form 4 filing 0001104659-19-047186
2019-04-09 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 3,999,990, acquired Open Form 4 filing 0001104659-19-020868
2019-02-19 S, Open-market sale Intercept Pharmaceuticals, Inc.ICPT 3,018,346, disposed Open Form 4 filing 0001104659-19-009925
2018-09-18 P, Open-market purchase Principia Biopharma Inc.PRNB 2,975,000, acquired Open Form 4 filing 0001104659-18-057814
2018-06-13 P, Open-market purchase Versartis, Inc.VSAR 112,928, acquired Open Form 4 filing 0001104659-18-040532
2018-06-08 P, Open-market purchase Versartis, Inc.VSAR 463,160, acquired Open Form 4 filing 0001104659-18-039258
2018-06-07 P, Open-market purchase Versartis, Inc.VSAR 301,964, acquired Open Form 4 filing 0001104659-18-039258
2018-06-06 P, Open-market purchase Versartis, Inc.VSAR 1,149,585, acquired Open Form 4 filing 0001104659-18-039258
2018-01-31 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 1,999,999, acquired Open Form 4 filing 0001209191-18-006777
2017-12-14 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 239,134, acquired Open Form 4 filing 0001209191-17-065785
2017-12-13 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 613,548, acquired Open Form 4 filing 0001209191-17-065785
2017-12-12 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 138,876, acquired Open Form 4 filing 0001209191-17-065785
2017-12-05 P, Open-market purchase Versartis, Inc.VSAR 85,790, acquired Open Form 4 filing 0001209191-17-064066
2017-12-04 P, Open-market purchase Versartis, Inc.VSAR 1,135,657, acquired Open Form 4 filing 0001209191-17-064066
2017-12-01 P, Open-market purchase Versartis, Inc.VSAR 893,961, acquired Open Form 4 filing 0001209191-17-064066
2017-03-24 P, Open-market purchase Versartis, Inc.VSAR 7,000,005, acquired Open Form 4 filing 0001209191-17-023214
2016-10-03 P, Open-market purchase Versartis, Inc.VSAR 7,000,005, acquired Open Form 4 filing 0001209191-16-143870
2015-10-13 P, Open-market purchase Aclaris Therapeutics, Inc.ACRS 4,499,990, acquired Open Form 4 filing 0001209191-15-075196
2015-10-06 P, Open-market purchase Mirna Therapeutics, Inc.MIRN 5,999,994, acquired Open Form 4 filing 0001144204-15-058275
2015-05-12 P, Open-market purchase aTYR Pharma IncLIFE 4,480,000, acquired Open Form 4 filing 0001209191-15-043030
2014-12-08 S, Open-market sale Histogenics CorpHSGX 11,022, disposed Open Form 4 filing 0001144204-14-073112

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 68
  • Open-market sale 120
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. AKKARAJU SRINIVAS, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001253170

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.